The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance

AIDS Research and Human Retroviruses

Volumn 15, Issue 4, 1999, Pages 355-363

  Vaillancourt, Marc ^a   Irlbeck, David ^a,b   Smith, Terri ^a   Coombs, Robert W ^c   Swanstrom, Ronald ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; SAQUINAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG FORMULATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, MICROBIAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MUTATION; REPRODUCIBILITY OF RESULTS; SAQUINAVIR;

EID: 0033041477     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311321     Document Type: Article

References (43)

1. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, and Moss B: An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci USA 1990;87:7472-7476.
2. Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck DW, Plattner JJ, Rittenhouse JW, Turon M, Wideburg N, Kohlbrenner WE, Simmer R, Helfrich R, Paul DA, and Knigge M: Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990;249:527-533.
3. McQuade TJ, Tomasselli AG, Liu L, Karacostas V, Moss B, Sawyer TK, Heinrikson RL, and Tarpley WG: A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 1990;247:454-456.
4. Meek TD, Lambert DM, Dreyer GB, Carr TJ, Tomaszek TA Jr, Moore ML, Strickler JE, Debouck C, Hyland LJ, Matthews TJ, Metcalf BW, and Petteway SR: Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (London) 1990;343:90-92.
5. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Krohn A, Lambert RW, Merret JH, Mills JS, Parkes KEB, Redshaw S, Ritchie AJ, Taylor DL, Thomas GJ, and Machin PJ: Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248:358-361.
6. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, and Mills JS: Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991;16: 295-305.
7. Vella S: Clinical experience with saquinavir. AIDS 1995;9(Suppl. 2):S21-25.
8. Collier AC, Coombs RW, Schoenfeld DA, Bassett R, Baruch A, and Corey L: Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res 1996;29:99.
9. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, and Corey L: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334:1011-1017.
10. Tamalet C, Lafeuillade A, Fantini J, Poggi C, and Yahi N: Quantification of HIV-1 viral load in lymphoid and blood cells: Assessment during four-drug combination therapy. AIDS 1997;11: 895-901.
11. Jacobsen H, Hanggi M, Ott M, Duncan IB, Owen S, Andreoni M, Vella S, and Mous J: In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies. J Infect Dis 1996;173:1379-1387.
12. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, and Mous J: Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995;206:527-534.
13. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, and Blair ED: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39: 1704-1710.
14. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, and Merigan TC: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-1050.
15. Ives KJ, Jacobsen H, Galpin SA, Gareav MM, Dorrell L, Mous J, Bragman K, and Weber JN: Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother 1997;39:771-779.
16. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ, and Emini EA: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 1995;374:569-571.
17. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H, and Emini EA: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-8276.
18. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo H, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CAB, Leonard JM, Norbeck DW, and Kempf DJ: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996;2:760-766.
19. BHIVA Guidelines Co-ordinating Committee: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-1092.
20. Roberts NA: Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995;9(Suppl. 2):S27-32.
21. Boucher C: Rational approaches to resistance: Using saquinavir. AIDS 1996;10(Suppl. 1):S15-19.
22. Salter RD, Howell DN, and Cresswell P: Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235-246.
23. Kimpton J and Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992;66:2232-2239.
24. Chen C and Okayama H: High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987;7:2745-2752.
25. Eustice DC, Feldman PA, Colberg PA, Buckery RM, and Neubauer RH: A sensitive method for the detection of beta-galactosidase in transfected mammalian cells. Biotechniques 1991;11:739-740.
26. + cell line H9. AIDS Res Hum Retroviruses 1989;5: 253-255.
27. Buckheit RJ and Swanstrom R: Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res Hum Retroviruses 1991;7:295-302.
28. Vandamme AM, Van DS, Kok W, Goubau P, Fransen K, Kievits T, Schmit JC, De Clercq E, and Desmyter J: Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. J Virol Methods 1995;52: 121-132.
29. Dyer JR, Gilliam BL, Eron JJ, Grosso L, Cohen MS, and Fiscus SA: Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: Comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Mtehods 1996;60;161-170.
30. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, and Leonard JM: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-660.
31. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM, and Back DJ: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11:F29-F33.
32. Winters MA, Shapiro JM, Lawrence J, and Merigan TC: Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998;72:5303-5306.
33. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, and Chodakewitz JA: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337: 734-739.
34. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, and Fischl MA: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
35. Eberle J, Bechowsky B, Rose D, Hauser U, Von Der Helm K, Gurtler L, and Nitschko H: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses 1995;11: 671-676.
36. Maschera B, Darby G, Palu G, Wright LL, Tisdale M, Myers R, Blair ED, and Furfine ES: Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem 1996;271:33231-33235.
37. Ermolieff J, Lin X, and Tang J: Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. Biochemistry 1997;36:12364-12370.
38. Wilson SI, Phylip LH, Mills JS, Gulnik SV, Erickson JW, Dunn BM, and Kay J: Escape mutants of HIV-1 proteinase: enzymatic efficiency and susceptibility to inhibition. Biochim Biophys Acta 1997;1339:113-125.
39. Lech WJ, Wang G, Yang YL, Chee Y, Dorman K, McCrae D, Lazzeroni LC, Erickson JW, Sinsheimer JS, and Kaplan AH: In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996;70:2038-2043.
40. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, and Gingeras TR: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996;2: 753-759.
41. Patick AK, Mo H, Markowitz M, Appell K, Wu B, Musick L, Kalish V, Kaldor S, Reich S, Ho D, and Weber S: Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996;40:292-297.
42. Para M: Executive Summary of Interim Analysis of ACTG 333: The anti-viral effect of switching from the hard capsule saquinavir (SQVhc) to the soft gelatin capsule of saquinavir (SQVsgc) vs. switching to indinavir (IDV) after one year of saquinavir use. March 21, 1997. http://www.aidsinfonyc.org/network/333.html
43. Dulioust A, Paulous S, Guillemot L, Boue G, Galanaud P, and Clavel F: Selection of saquinavir-resistant mutants by indinavir following a switch from saquinavir. In International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication: Program and Abstracts. St. Petersburg, FL, 1997. International Medical Press, London, U.K. [Abstract 16]